Macrophage-Associated Mesenchymal Stem Cells Assume an Activated, Migratory, Pro-Inflammatory Phenotype with Increased IL-6 and CXCL10 Secretion

Kevin Anton(Rutgers, The State University of New Jersey), John Glod(National Institutes of Health)
PLoS ONE
April 4, 2012
10.1371/journal.pone.0035036
Cited by 138

Related Papers

Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities
|Journal of Pediatric Hematology/Oncology|2016|37
A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
|Clinical Cancer Research|2022|22
Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
|Unknown|2023|0
Supplementary Appendix S1 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
|Unknown|2023|0
Data from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
|Unknown|2023|0